- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo - Additionally, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback